Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website    Save this grant
Crystal ball icon
Predicted Deadline
The next cycle for this opportunity is predicted based on past data. If you save this grant, we’ll notify you if there are any changes.

Next predicted deadline: Oct 21, 2023 (Letter of inquiry)

Later predicted deadlines: Nov 21, 2023 (Full proposal), Nov 21, 2023 (Letter of inquiry), Dec 21, 2023 (Full proposal), Jan 21, 2024 (Letter of inquiry), Feb 21, 2024 (Full proposal), Mar 21, 2024 (Letter of inquiry), Apr 21, 2024 (Full proposal), Jun 22, 2024 (Letter of inquiry), Jul 22, 2024 (Full proposal), Oct 21, 2024 (Letter of inquiry), Nov 21, 2024 (Full proposal)

Grant amount: Up to US $600,000

Fields of work: Medical Technology & Devices Cardiovascular Diseases & Systems Respiratory Diseases & Systems Hematological Systems Sleep

Applicant type: Government Entity, Nonprofit, For-Profit Business, Indigenous Group

Funding uses: Research

Location of project: Anywhere in the world

Location of residency: United States, American Samoa, Guam, Northern Mariana Islands, Puerto Rico Show all


NOTE: All types of non-AIDS applications allowed for this funding opportunity announcement are due by 5:00 PM local time of applicant organization on these dates:

  • November 21, 2022
  • February 21, 2023 
  • July 21, 2023
  • November 21, 2023
  • February 21, 2024
  • July 22, 2024
  • November 21, 2024

All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due by 5:00 PM local time of applicant organization on these dates:

  • December 21, 2022
  • April 18, 2023
  • August 18, 2023
  • December 21, 2023
  • April 18, 2024
  • August 19, 2024
  • December 20, 2024

This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption. Well-suited applications must offer the potential to accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This FOA is part of a suite of NHLBI Catalyze program to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Product Definition or Preclinical FOAs.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Other Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

This page was last reviewed May 09, 2023 and last updated May 09, 2023